News for SAGE Therapeutics Stock (SAGE)

The Schall Law Firm Is Looking Into Allegations Against Sage Therapeutics Inc. For Securities Violations And Invites Investors To Join

Accesswire • 08/17/24

The Schall Law Firm Is Investigating Sage Therapeutics Inc. For Securities Violations And Seeks Stockholders With Losses To Join

Accesswire • 08/16/24

The Schall Law Firm Is Looking Into Sage Therapeutics Inc. For Securities Violations And Invites Investors With Losses To Join In Conversation

Accesswire • 08/15/24

The Schall Law Firm Is Investigating Sage Therapeutics Inc. For Potential Securities Violations And Encourages Investors Who Have Incurred Losses To Engage In Discussions

Accesswire • 08/15/24

The Schall Law Firm Is Investigating Sage Therapeutics Inc. For Potential Securities Violations And Urges Investors Who Have Incurred Losses To Initiate Discussions

Accesswire • 08/14/24

The Schall Law Firm Is Investigating Sage Therapeutics Inc. For Potential Securities Violations And Encourages Investors Who Have Incurred Losses To Initiate Discussions

Accesswire • 08/13/24

Sage Therapeutics Inc Is Under The Schall Law Firm's Probe For Possible Securities Breaches And Investors With Losses Are Encouraged To Begin Conversations

Accesswire • 08/09/24

Sage Therapeutics Inc Is Being Investigated By The Schall Law Firm For Potential Securities Violations And Investors With Losses Are Urged To Initiate Dialogue

Accesswire • 08/08/24

Sage Therapeutics, Inc. (SAGE) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings

Accesswire • 08/08/24

Sage Therapeutics Inc Is Under Investigation By The Schall Law Firm For Potential Securities Violations, And Investors With Losses Are Encouraged To Initiate Dialogue

Accesswire • 08/07/24

Sage Therapeutics Inc Investigated By The Schall Law Firm For Possible Securities Violations Investors With Losses Urged To Engage In Dialogue

Accesswire • 08/06/24

Sage Therapeutics (SAGE) Q2 Loss Wider Than Expected, Sales Rise

Zacks Investment Research • 08/01/24

Sage Therapeutics, Inc., (SAGE) Q2 2024 Earnings Call Transcript

Seeking Alpha • 08/01/24

Sage Therapeutics, Inc. (SAGE) Reports Q2 Loss, Tops Revenue Estimates

Zacks Investment Research • 07/31/24

Sage Therapeutics Announces Second Quarter 2024 Financial Results and Highlights Pipeline and Business Progress

Business Wire • 07/31/24

Sage Therapeutics, Inc. (SAGE) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

Zacks Investment Research • 07/24/24

Sage Therapeutics Stock Slides as Pipeline Thins

Barrons • 07/24/24

Sage Therapeutics Collapses 21% After Biogen-Tied Essential Tremor Drug Fails

Investors Business Daily • 07/24/24

Sage Therapeutics' stock dives as failed trial hits Biogen collaboration

Market Watch • 07/24/24

Sage Therapeutics Inc Investigated By The Schall Law Firm For Possible Securities Violations, Investors With Losses Urged To Engage In Dialogue

Accesswire • 07/23/24

Sage Therapeutics Inc Is Under Investigation By The Schall Law Firm For Possible Securities Violations And Investors With Losses Are Encouraged To Initiate Dialogue

Accesswire • 07/23/24

Sage Therapeutics Inc Is Under Investigation By The Schall Law Firm For Possible Securities Violations And Investors With Losses Are Urged To Start Dialogues

Accesswire • 07/19/24

SAGE Rides on Zurzuvae Sales, Pipeline Setbacks a Concern

Zacks Investment Research • 07/19/24

The Schall Law Firm Is Investigating Sage Therapeutics Inc For Potential Securities Breaches And Encourages Investors Who Have Experienced Losses To Initiate Dialogues

Accesswire • 07/18/24

Sage Therapeutics Inc Is Under Examination For Possible Securities Violations By The Schall Law Firm, Investors Who Have Suffered Losses Are Urged To Begin Conversations

Accesswire • 07/17/24